theMednetRegister

Rheumatology

Glomerulonephritis   

Questions discussed in this category

What is your treatment approach when managing patients with relapsing lupus nephritis who previously achieved remission with mycophenolate and steroids?
5 Answers available
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
1 Answer available
Do you ever combine voclosporin and belimumab in the treatment of lupus nephritis?
Do you use them sequentially or together?
3 Answers available
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
1 Answer available
How would you manage a patient with CKD4 due to lupus nephritis of unknown class who develops AKI requiring hemodialysis and nephrotic range proteinuria and is found to have atrophic kidneys on imaging?
3 Answers available
What is your approach for steroid dosing for patients with ANCA vasculitis on induction treatment with rituximab, avacopan, and glucocorticoid therapy?
1 Answer available
What are your management strategies for patients with biopsy proven IgA nephropathy with rapidly progressive glomerulonephritis?
2 Answers available
How do you manage a pregnant patient with lupus who develops renal disease during pregnancy that is not due to pre-eclampsia?
2 Answers available
Would you use voclosporin or belimumab as adjunctive therapy for treatment of lupus nephritis?
How does the presence of extra-renal manifestations influence this decision?
8 Answers available
What is your threshold to repeat a kidney biopsy in a patient with a history of lupus nephritis who is on maintenance therapy and develops subtle changes in urinary protein excretion or microscopic hematuria?
3 Answers available
What drives you to choose voclospsorin over tacrolimus given the substantially higher cost?
2 Answers available
How do you determine duration of therapy for patients who have responded well to voclosporin therapy?
How do you monitor response and what do you consider a satisfactory response? Do you aim for a certain threshold of proteinuria?
3 Answers available
When would you administer the next maintenance dose of rituximab in a patient with ANCA glomerulonephritis who last received an infusion six months ago and has low immunoglobulin levels and an undetectable CD-19 cell count?
1 Answer available
How do you approach discussing the pill burden of voclosporin with patients who already have to take a regimen such as MMF+HCQ+ACEi and possibly more?
2 Answers available
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
1 Answer available
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
2 Answers available
For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
1 Answer available
In which patients with suspected IgA nephropathy and microalbuminuria would you recommend a kidney biopsy?
1 Answer available
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
2 Answers available
Would you treat a patient aggressively for lupus nephritis if they have persistent proteinuria over 1 gram but cannot get a timely kidney biopsy?
3 Answers available
What would be the clinical role of SGLT-2 inhibitors for lupus nephritis given it has an indication for proteinuria related to CKD?
5 Answers available
When would you consider a kidney biopsy in a patient with longstanding diabetes and hypertension (baseline creatinine 4-5, 4+ proteinuria) who was recently found to have dsDNA positivity?
1 Answer available
Would you check ANCA titers in a patient with a history of PR-3-ANCA glomerulonephritis in remission and a stable creatinine but with recurrent microscopic hematuria?
6 Answers available
Is there a role for eculizumab in the management of refractory lupus nephritis?
3 Answers available
When is a kidney biopsy warranted in a patient with possible scleroderma renal crisis?
1 Answer available


Papers discussed in this category

Kidney international, 2019-01
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
N Engl J Med,
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Clinical journal of the American Society of Nephrology : CJASN, 2008-01
Value of a complete or partial remission in severe lupus nephritis.
Lancet, 2021 May 07
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet (London, England), 2011 Feb 04
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 19
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Rheumatology international, 2017 Mar 03
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
Rheumatology (Oxford, England), 2015 Aug 27
Eculizumab as rescue therapy in severe resistant lupus nephritis.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017 Mar-Apr
Biopsy of small kidneys: A safe and a useful guide to potentially treatable kidney disease.
Clinical journal of the American Society of Nephrology : CJASN, 2017 May 04
Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013 Jun 19
Severe lupus nephritis: the predictive value of a ≥ 50% reduction in proteinuria at 6 months.
Clinical journal of the American Society of Nephrology : CJASN, 2020 Mar 09
The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
Kidney international, 2021 Apr 18
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
The New England journal of medicine, 2022 Nov 04
Empagliflozin in Patients with Chronic Kidney Disease.
Lupus science & medicine, 2020 Feb 18
Prediction of prognosis and renal outcome in lupus nephritis.
N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Lupus Sci Med, 2018
Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis.
Annals of the rheumatic diseases, 2024 Jan 11
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012-08
Cyclophosphamide without corticosteroids for treatment of severe systemic necrotizing vasculitis.
Current medical research and opinion, 2016-12
Corticosteroids: the knee jerk response.
Cancer, 2006-09-15
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
Journal of the National Medical Association, 1979 Feb
Administration of cyclophosphamide during late pregnancy and early lactation: a case report.
Annals of the rheumatic diseases, 2023 Oct 12
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Kidney international, 2024 Jan
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.
Lupus, 2023 Sep 27
Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.
Arthritis Rheumatol, 2020 Aug 4
CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Cureus, 2023 May 10
Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis.
BMJ open, 2019 Dec 16
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Annals of the rheumatic diseases, 2024 Oct 21
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.
Journal of the American Society of Nephrology : JASN, 2009-05
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011-12
The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.
Annals of internal medicine, 2015 Jan 06
Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003-07
Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide.
Arthritis and rheumatism, 2013-07
Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.
Lupus,
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Arthritis care & research, 2023 Nov 28
Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023 Mar 31
The influence of repeated flares in response to therapy and prognosis in lupus nephritis.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.